Report Detail

Pharma & Healthcare Global Chimeric Antigen Receptor (CAR) T-Cell Therapy Market 2023 by Company, Regions, Type and Application, Forecast to 2029

  • RnM4526333
  • |
  • 27 March, 2023
  • |
  • Global
  • |
  • 104 Pages
  • |
  • GIR (Global Info Research)
  • |
  • Pharma & Healthcare

According to our (Global Info Research) latest study, the global Chimeric Antigen Receptor (CAR) T-Cell Therapy market size was valued at USD million in 2022 and is forecast to a readjusted size of USD million by 2029 with a CAGR of % during review period. The influence of COVID-19 and the Russia-Ukraine War were considered while estimating market sizes.
Chimeric antigen receptor (CAR) T-cell therapy is a way to get immune cells called T cells (a type of white blood cell) to fight cancer by changing them in the lab so they can find and destroy cancer cells. CAR T-cell therapy is also sometimes talked about as a type of cell-based gene therapy, because it involves altering the genes inside T cells to help them attack the cancer.
This report is a detailed and comprehensive analysis for global Chimeric Antigen Receptor (CAR) T-Cell Therapy market. Both quantitative and qualitative analyses are presented by company, by region & country, by Type and by Application. As the market is constantly changing, this report explores the competition, supply and demand trends, as well as key factors that contribute to its changing demands across many markets. Company profiles and product examples of selected competitors, along with market share estimates of some of the selected leaders for the year 2023, are provided.
Key Features:
Global Chimeric Antigen Receptor (CAR) T-Cell Therapy market size and forecasts, in consumption value ($ Million), 2018-2029
Global Chimeric Antigen Receptor (CAR) T-Cell Therapy market size and forecasts by region and country, in consumption value ($ Million), 2018-2029
Global Chimeric Antigen Receptor (CAR) T-Cell Therapy market size and forecasts, by Type and by Application, in consumption value ($ Million), 2018-2029
Global Chimeric Antigen Receptor (CAR) T-Cell Therapy market shares of main players, in revenue ($ Million), 2018-2023
The Primary Objectives in This Report Are:
To determine the size of the total market opportunity of global and key countries
To assess the growth potential for Chimeric Antigen Receptor (CAR) T-Cell Therapy
To forecast future growth in each product and end-use market
To assess competitive factors affecting the marketplace
This report profiles key players in the global Chimeric Antigen Receptor (CAR) T-Cell Therapy market based on the following parameters - company overview, production, value, price, gross margin, product portfolio, geographical presence, and key developments. Key companies covered as a part of this study include Novartis, Gilead Sciences, Bristol-Myers Squibb, J & J and JW Therapeutics, etc.
This report also provides key insights about market drivers, restraints, opportunities, new product launches or approvals, COVID-19 and Russia-Ukraine War Influence.
Market segmentation
Chimeric Antigen Receptor (CAR) T-Cell Therapy market is split by Type and by Application. For the period 2018-2029, the growth among segments provide accurate calculations and forecasts for consumption value by Type and by Application. This analysis can help you expand your business by targeting qualified niche markets.
Market segment by Type
CD19-targeted
BCMA-targeted
Market segment by Application
Lymphoma
Multiple Myeloma
Market segment by players, this report covers
Novartis
Gilead Sciences
Bristol-Myers Squibb
J & J
JW Therapeutics
FOSUNKite
CARsgen Therapeutics
Autolus Therapeutics
Sorrento Therapeutics
Mustang Bio
Bluebird Bio
Cellectis
Allogene Therapeutics
Celyad
Market segment by regions, regional analysis covers
North America (United States, Canada, and Mexico)
Europe (Germany, France, UK, Russia, Italy, and Rest of Europe)
Asia-Pacific (China, Japan, South Korea, India, Southeast Asia, Australia and Rest of Asia-Pacific)
South America (Brazil, Argentina and Rest of South America)
Middle East & Africa (Turkey, Saudi Arabia, UAE, Rest of Middle East & Africa)
The content of the study subjects, includes a total of 13 chapters:
Chapter 1, to describe Chimeric Antigen Receptor (CAR) T-Cell Therapy product scope, market overview, market estimation caveats and base year.
Chapter 2, to profile the top players of Chimeric Antigen Receptor (CAR) T-Cell Therapy, with revenue, gross margin and global market share of Chimeric Antigen Receptor (CAR) T-Cell Therapy from 2018 to 2023.
Chapter 3, the Chimeric Antigen Receptor (CAR) T-Cell Therapy competitive situation, revenue and global market share of top players are analyzed emphatically by landscape contrast.
Chapter 4 and 5, to segment the market size by Type and application, with consumption value and growth rate by Type, application, from 2018 to 2029.
Chapter 6, 7, 8, 9, and 10, to break the market size data at the country level, with revenue and market share for key countries in the world, from 2018 to 2023.and Chimeric Antigen Receptor (CAR) T-Cell Therapy market forecast, by regions, type and application, with consumption value, from 2024 to 2029.
Chapter 11, market dynamics, drivers, restraints, trends, Porters Five Forces analysis, and Influence of COVID-19 and Russia-Ukraine War
Chapter 12, the key raw materials and key suppliers, and industry chain of Chimeric Antigen Receptor (CAR) T-Cell Therapy.
Chapter 13, to describe Chimeric Antigen Receptor (CAR) T-Cell Therapy research findings and conclusion.


1 Market Overview

  • 1.1 Product Overview and Scope of Chimeric Antigen Receptor (CAR) T-Cell Therapy
  • 1.2 Market Estimation Caveats and Base Year
  • 1.3 Classification of Chimeric Antigen Receptor (CAR) T-Cell Therapy by Type
    • 1.3.1 Overview: Global Chimeric Antigen Receptor (CAR) T-Cell Therapy Market Size by Type: 2018 Versus 2022 Versus 2029
    • 1.3.2 Global Chimeric Antigen Receptor (CAR) T-Cell Therapy Consumption Value Market Share by Type in 2022
    • 1.3.3 CD19-targeted
    • 1.3.4 BCMA-targeted
  • 1.4 Global Chimeric Antigen Receptor (CAR) T-Cell Therapy Market by Application
    • 1.4.1 Overview: Global Chimeric Antigen Receptor (CAR) T-Cell Therapy Market Size by Application: 2018 Versus 2022 Versus 2029
    • 1.4.2 Lymphoma
    • 1.4.3 Multiple Myeloma
  • 1.5 Global Chimeric Antigen Receptor (CAR) T-Cell Therapy Market Size & Forecast
  • 1.6 Global Chimeric Antigen Receptor (CAR) T-Cell Therapy Market Size and Forecast by Region
    • 1.6.1 Global Chimeric Antigen Receptor (CAR) T-Cell Therapy Market Size by Region: 2018 VS 2022 VS 2029
    • 1.6.2 Global Chimeric Antigen Receptor (CAR) T-Cell Therapy Market Size by Region, (2018-2029)
    • 1.6.3 North America Chimeric Antigen Receptor (CAR) T-Cell Therapy Market Size and Prospect (2018-2029)
    • 1.6.4 Europe Chimeric Antigen Receptor (CAR) T-Cell Therapy Market Size and Prospect (2018-2029)
    • 1.6.5 Asia-Pacific Chimeric Antigen Receptor (CAR) T-Cell Therapy Market Size and Prospect (2018-2029)
    • 1.6.6 South America Chimeric Antigen Receptor (CAR) T-Cell Therapy Market Size and Prospect (2018-2029)
    • 1.6.7 Middle East and Africa Chimeric Antigen Receptor (CAR) T-Cell Therapy Market Size and Prospect (2018-2029)

2 Company Profiles

  • 2.1 Novartis
    • 2.1.1 Novartis Details
    • 2.1.2 Novartis Major Business
    • 2.1.3 Novartis Chimeric Antigen Receptor (CAR) T-Cell Therapy Product and Solutions
    • 2.1.4 Novartis Chimeric Antigen Receptor (CAR) T-Cell Therapy Revenue, Gross Margin and Market Share (2018-2023)
    • 2.1.5 Novartis Recent Developments and Future Plans
  • 2.2 Gilead Sciences
    • 2.2.1 Gilead Sciences Details
    • 2.2.2 Gilead Sciences Major Business
    • 2.2.3 Gilead Sciences Chimeric Antigen Receptor (CAR) T-Cell Therapy Product and Solutions
    • 2.2.4 Gilead Sciences Chimeric Antigen Receptor (CAR) T-Cell Therapy Revenue, Gross Margin and Market Share (2018-2023)
    • 2.2.5 Gilead Sciences Recent Developments and Future Plans
  • 2.3 Bristol-Myers Squibb
    • 2.3.1 Bristol-Myers Squibb Details
    • 2.3.2 Bristol-Myers Squibb Major Business
    • 2.3.3 Bristol-Myers Squibb Chimeric Antigen Receptor (CAR) T-Cell Therapy Product and Solutions
    • 2.3.4 Bristol-Myers Squibb Chimeric Antigen Receptor (CAR) T-Cell Therapy Revenue, Gross Margin and Market Share (2018-2023)
    • 2.3.5 Bristol-Myers Squibb Recent Developments and Future Plans
  • 2.4 J & J
    • 2.4.1 J & J Details
    • 2.4.2 J & J Major Business
    • 2.4.3 J & J Chimeric Antigen Receptor (CAR) T-Cell Therapy Product and Solutions
    • 2.4.4 J & J Chimeric Antigen Receptor (CAR) T-Cell Therapy Revenue, Gross Margin and Market Share (2018-2023)
    • 2.4.5 J & J Recent Developments and Future Plans
  • 2.5 JW Therapeutics
    • 2.5.1 JW Therapeutics Details
    • 2.5.2 JW Therapeutics Major Business
    • 2.5.3 JW Therapeutics Chimeric Antigen Receptor (CAR) T-Cell Therapy Product and Solutions
    • 2.5.4 JW Therapeutics Chimeric Antigen Receptor (CAR) T-Cell Therapy Revenue, Gross Margin and Market Share (2018-2023)
    • 2.5.5 JW Therapeutics Recent Developments and Future Plans
  • 2.6 FOSUNKite
    • 2.6.1 FOSUNKite Details
    • 2.6.2 FOSUNKite Major Business
    • 2.6.3 FOSUNKite Chimeric Antigen Receptor (CAR) T-Cell Therapy Product and Solutions
    • 2.6.4 FOSUNKite Chimeric Antigen Receptor (CAR) T-Cell Therapy Revenue, Gross Margin and Market Share (2018-2023)
    • 2.6.5 FOSUNKite Recent Developments and Future Plans
  • 2.7 CARsgen Therapeutics
    • 2.7.1 CARsgen Therapeutics Details
    • 2.7.2 CARsgen Therapeutics Major Business
    • 2.7.3 CARsgen Therapeutics Chimeric Antigen Receptor (CAR) T-Cell Therapy Product and Solutions
    • 2.7.4 CARsgen Therapeutics Chimeric Antigen Receptor (CAR) T-Cell Therapy Revenue, Gross Margin and Market Share (2018-2023)
    • 2.7.5 CARsgen Therapeutics Recent Developments and Future Plans
  • 2.8 Autolus Therapeutics
    • 2.8.1 Autolus Therapeutics Details
    • 2.8.2 Autolus Therapeutics Major Business
    • 2.8.3 Autolus Therapeutics Chimeric Antigen Receptor (CAR) T-Cell Therapy Product and Solutions
    • 2.8.4 Autolus Therapeutics Chimeric Antigen Receptor (CAR) T-Cell Therapy Revenue, Gross Margin and Market Share (2018-2023)
    • 2.8.5 Autolus Therapeutics Recent Developments and Future Plans
  • 2.9 Sorrento Therapeutics
    • 2.9.1 Sorrento Therapeutics Details
    • 2.9.2 Sorrento Therapeutics Major Business
    • 2.9.3 Sorrento Therapeutics Chimeric Antigen Receptor (CAR) T-Cell Therapy Product and Solutions
    • 2.9.4 Sorrento Therapeutics Chimeric Antigen Receptor (CAR) T-Cell Therapy Revenue, Gross Margin and Market Share (2018-2023)
    • 2.9.5 Sorrento Therapeutics Recent Developments and Future Plans
  • 2.10 Mustang Bio
    • 2.10.1 Mustang Bio Details
    • 2.10.2 Mustang Bio Major Business
    • 2.10.3 Mustang Bio Chimeric Antigen Receptor (CAR) T-Cell Therapy Product and Solutions
    • 2.10.4 Mustang Bio Chimeric Antigen Receptor (CAR) T-Cell Therapy Revenue, Gross Margin and Market Share (2018-2023)
    • 2.10.5 Mustang Bio Recent Developments and Future Plans
  • 2.11 Bluebird Bio
    • 2.11.1 Bluebird Bio Details
    • 2.11.2 Bluebird Bio Major Business
    • 2.11.3 Bluebird Bio Chimeric Antigen Receptor (CAR) T-Cell Therapy Product and Solutions
    • 2.11.4 Bluebird Bio Chimeric Antigen Receptor (CAR) T-Cell Therapy Revenue, Gross Margin and Market Share (2018-2023)
    • 2.11.5 Bluebird Bio Recent Developments and Future Plans
  • 2.12 Cellectis
    • 2.12.1 Cellectis Details
    • 2.12.2 Cellectis Major Business
    • 2.12.3 Cellectis Chimeric Antigen Receptor (CAR) T-Cell Therapy Product and Solutions
    • 2.12.4 Cellectis Chimeric Antigen Receptor (CAR) T-Cell Therapy Revenue, Gross Margin and Market Share (2018-2023)
    • 2.12.5 Cellectis Recent Developments and Future Plans
  • 2.13 Allogene Therapeutics
    • 2.13.1 Allogene Therapeutics Details
    • 2.13.2 Allogene Therapeutics Major Business
    • 2.13.3 Allogene Therapeutics Chimeric Antigen Receptor (CAR) T-Cell Therapy Product and Solutions
    • 2.13.4 Allogene Therapeutics Chimeric Antigen Receptor (CAR) T-Cell Therapy Revenue, Gross Margin and Market Share (2018-2023)
    • 2.13.5 Allogene Therapeutics Recent Developments and Future Plans
  • 2.14 Celyad
    • 2.14.1 Celyad Details
    • 2.14.2 Celyad Major Business
    • 2.14.3 Celyad Chimeric Antigen Receptor (CAR) T-Cell Therapy Product and Solutions
    • 2.14.4 Celyad Chimeric Antigen Receptor (CAR) T-Cell Therapy Revenue, Gross Margin and Market Share (2018-2023)
    • 2.14.5 Celyad Recent Developments and Future Plans

3 Market Competition, by Players

  • 3.1 Global Chimeric Antigen Receptor (CAR) T-Cell Therapy Revenue and Share by Players (2018-2023)
  • 3.2 Market Share Analysis (2022)
    • 3.2.1 Market Share of Chimeric Antigen Receptor (CAR) T-Cell Therapy by Company Revenue
    • 3.2.2 Top 3 Chimeric Antigen Receptor (CAR) T-Cell Therapy Players Market Share in 2022
    • 3.2.3 Top 6 Chimeric Antigen Receptor (CAR) T-Cell Therapy Players Market Share in 2022
  • 3.3 Chimeric Antigen Receptor (CAR) T-Cell Therapy Market: Overall Company Footprint Analysis
    • 3.3.1 Chimeric Antigen Receptor (CAR) T-Cell Therapy Market: Region Footprint
    • 3.3.2 Chimeric Antigen Receptor (CAR) T-Cell Therapy Market: Company Product Type Footprint
    • 3.3.3 Chimeric Antigen Receptor (CAR) T-Cell Therapy Market: Company Product Application Footprint
  • 3.4 New Market Entrants and Barriers to Market Entry
  • 3.5 Mergers, Acquisition, Agreements, and Collaborations

4 Market Size Segment by Type

  • 4.1 Global Chimeric Antigen Receptor (CAR) T-Cell Therapy Consumption Value and Market Share by Type (2018-2023)
  • 4.2 Global Chimeric Antigen Receptor (CAR) T-Cell Therapy Market Forecast by Type (2024-2029)

5 Market Size Segment by Application

  • 5.1 Global Chimeric Antigen Receptor (CAR) T-Cell Therapy Consumption Value Market Share by Application (2018-2023)
  • 5.2 Global Chimeric Antigen Receptor (CAR) T-Cell Therapy Market Forecast by Application (2024-2029)

6 North America

  • 6.1 North America Chimeric Antigen Receptor (CAR) T-Cell Therapy Consumption Value by Type (2018-2029)
  • 6.2 North America Chimeric Antigen Receptor (CAR) T-Cell Therapy Consumption Value by Application (2018-2029)
  • 6.3 North America Chimeric Antigen Receptor (CAR) T-Cell Therapy Market Size by Country
    • 6.3.1 North America Chimeric Antigen Receptor (CAR) T-Cell Therapy Consumption Value by Country (2018-2029)
    • 6.3.2 United States Chimeric Antigen Receptor (CAR) T-Cell Therapy Market Size and Forecast (2018-2029)
    • 6.3.3 Canada Chimeric Antigen Receptor (CAR) T-Cell Therapy Market Size and Forecast (2018-2029)
    • 6.3.4 Mexico Chimeric Antigen Receptor (CAR) T-Cell Therapy Market Size and Forecast (2018-2029)

7 Europe

  • 7.1 Europe Chimeric Antigen Receptor (CAR) T-Cell Therapy Consumption Value by Type (2018-2029)
  • 7.2 Europe Chimeric Antigen Receptor (CAR) T-Cell Therapy Consumption Value by Application (2018-2029)
  • 7.3 Europe Chimeric Antigen Receptor (CAR) T-Cell Therapy Market Size by Country
    • 7.3.1 Europe Chimeric Antigen Receptor (CAR) T-Cell Therapy Consumption Value by Country (2018-2029)
    • 7.3.2 Germany Chimeric Antigen Receptor (CAR) T-Cell Therapy Market Size and Forecast (2018-2029)
    • 7.3.3 France Chimeric Antigen Receptor (CAR) T-Cell Therapy Market Size and Forecast (2018-2029)
    • 7.3.4 United Kingdom Chimeric Antigen Receptor (CAR) T-Cell Therapy Market Size and Forecast (2018-2029)
    • 7.3.5 Russia Chimeric Antigen Receptor (CAR) T-Cell Therapy Market Size and Forecast (2018-2029)
    • 7.3.6 Italy Chimeric Antigen Receptor (CAR) T-Cell Therapy Market Size and Forecast (2018-2029)

8 Asia-Pacific

  • 8.1 Asia-Pacific Chimeric Antigen Receptor (CAR) T-Cell Therapy Consumption Value by Type (2018-2029)
  • 8.2 Asia-Pacific Chimeric Antigen Receptor (CAR) T-Cell Therapy Consumption Value by Application (2018-2029)
  • 8.3 Asia-Pacific Chimeric Antigen Receptor (CAR) T-Cell Therapy Market Size by Region
    • 8.3.1 Asia-Pacific Chimeric Antigen Receptor (CAR) T-Cell Therapy Consumption Value by Region (2018-2029)
    • 8.3.2 China Chimeric Antigen Receptor (CAR) T-Cell Therapy Market Size and Forecast (2018-2029)
    • 8.3.3 Japan Chimeric Antigen Receptor (CAR) T-Cell Therapy Market Size and Forecast (2018-2029)
    • 8.3.4 South Korea Chimeric Antigen Receptor (CAR) T-Cell Therapy Market Size and Forecast (2018-2029)
    • 8.3.5 India Chimeric Antigen Receptor (CAR) T-Cell Therapy Market Size and Forecast (2018-2029)
    • 8.3.6 Southeast Asia Chimeric Antigen Receptor (CAR) T-Cell Therapy Market Size and Forecast (2018-2029)
    • 8.3.7 Australia Chimeric Antigen Receptor (CAR) T-Cell Therapy Market Size and Forecast (2018-2029)

9 South America

  • 9.1 South America Chimeric Antigen Receptor (CAR) T-Cell Therapy Consumption Value by Type (2018-2029)
  • 9.2 South America Chimeric Antigen Receptor (CAR) T-Cell Therapy Consumption Value by Application (2018-2029)
  • 9.3 South America Chimeric Antigen Receptor (CAR) T-Cell Therapy Market Size by Country
    • 9.3.1 South America Chimeric Antigen Receptor (CAR) T-Cell Therapy Consumption Value by Country (2018-2029)
    • 9.3.2 Brazil Chimeric Antigen Receptor (CAR) T-Cell Therapy Market Size and Forecast (2018-2029)
    • 9.3.3 Argentina Chimeric Antigen Receptor (CAR) T-Cell Therapy Market Size and Forecast (2018-2029)

10 Middle East & Africa

  • 10.1 Middle East & Africa Chimeric Antigen Receptor (CAR) T-Cell Therapy Consumption Value by Type (2018-2029)
  • 10.2 Middle East & Africa Chimeric Antigen Receptor (CAR) T-Cell Therapy Consumption Value by Application (2018-2029)
  • 10.3 Middle East & Africa Chimeric Antigen Receptor (CAR) T-Cell Therapy Market Size by Country
    • 10.3.1 Middle East & Africa Chimeric Antigen Receptor (CAR) T-Cell Therapy Consumption Value by Country (2018-2029)
    • 10.3.2 Turkey Chimeric Antigen Receptor (CAR) T-Cell Therapy Market Size and Forecast (2018-2029)
    • 10.3.3 Saudi Arabia Chimeric Antigen Receptor (CAR) T-Cell Therapy Market Size and Forecast (2018-2029)
    • 10.3.4 UAE Chimeric Antigen Receptor (CAR) T-Cell Therapy Market Size and Forecast (2018-2029)

11 Market Dynamics

  • 11.1 Chimeric Antigen Receptor (CAR) T-Cell Therapy Market Drivers
  • 11.2 Chimeric Antigen Receptor (CAR) T-Cell Therapy Market Restraints
  • 11.3 Chimeric Antigen Receptor (CAR) T-Cell Therapy Trends Analysis
  • 11.4 Porters Five Forces Analysis
    • 11.4.1 Threat of New Entrants
    • 11.4.2 Bargaining Power of Suppliers
    • 11.4.3 Bargaining Power of Buyers
    • 11.4.4 Threat of Substitutes
    • 11.4.5 Competitive Rivalry
  • 11.5 Influence of COVID-19 and Russia-Ukraine War
    • 11.5.1 Influence of COVID-19
    • 11.5.2 Influence of Russia-Ukraine War

12 Industry Chain Analysis

  • 12.1 Chimeric Antigen Receptor (CAR) T-Cell Therapy Industry Chain
  • 12.2 Chimeric Antigen Receptor (CAR) T-Cell Therapy Upstream Analysis
  • 12.3 Chimeric Antigen Receptor (CAR) T-Cell Therapy Midstream Analysis
  • 12.4 Chimeric Antigen Receptor (CAR) T-Cell Therapy Downstream Analysis

13 Research Findings and Conclusion

    14 Appendix

    • 14.1 Methodology
    • 14.2 Research Process and Data Source

    Summary:
    Get latest Market Research Reports on Chimeric Antigen Receptor (CAR) T-Cell Therapy. Industry analysis & Market Report on Chimeric Antigen Receptor (CAR) T-Cell Therapy is a syndicated market report, published as Global Chimeric Antigen Receptor (CAR) T-Cell Therapy Market 2023 by Company, Regions, Type and Application, Forecast to 2029. It is complete Research Study and Industry Analysis of Chimeric Antigen Receptor (CAR) T-Cell Therapy market, to understand, Market Demand, Growth, trends analysis and Factor Influencing market.

    Last updated on

    REPORT YOU MIGHT BE INTERESTED

    Purchase this Report

    $3,480.00
    $5,220.00
    $6,960.00
    2,690.04
    4,035.06
    5,380.08
    3,208.56
    4,812.84
    6,417.12
    531,604.80
    797,407.20
    1,063,209.60
    292,702.80
    439,054.20
    585,405.60
    Credit card Logo

    Related Reports


    Reason to Buy

    Request for Sample of this report